New Page 1

Dr. Vladimir Vainstein

Vladimir Vladimir is a Medical Doctor at the Hadassah Medical Center in Jerusalem. He holds a B.Sc. degree in Medical Sciences from the Hebrew University, M.D. degree from the Hebrew University/ Hadassah Medical School and M.Sc. degree from the Department of Experimental Medicine and Cancer Research in the faculty of Medicine at the Hebrew University of Jerusalem. His M.Sc. research- carried out under the supervision of Prof. S.A. Ben-Sasson, involved the use of pathway inhibitors for the C-terminal post-translational modification of proteins, as a possible avenue for developing anti-angiogenesis therapy. Dr Vainstein is a fellow in Internal medicine Department at Hadassah Medical Center Campus Mt Scopus, Jerusalem. In IMBM he takes part in the immunotherapy project, investigating methods for improving the efficacy of monoclonal antibody drugs by mathemathically modeling the effects of such drugs on target and immune cells.

Scientific activity in 2007

Application of human granulopoiesis model to optimization of chemotherapeutic and supportive treatment in cancer patients. Analysis of clinical data of drug-induced neutropenia for taxotere and temodal in collaboration with Oncology Department of Soroka Hospital (Be'er-Sheva, Israel) and Neuro-oncology Unit of Hadassah Medical Center (Jerusalem, Israel). The work is a joint project with Optimata, Ltd.

Implementation of a comprehensive model of the pharmacokinetics of cytotoxic monoclonal antibodies at the cellular level to experimental data of interaction of conjugated anti-CD33 antibodies with human leukemia cells (in collaboration with Dr V. van der Velden, Erasmus University, Rotterdam, Israel).

Development of generic model of cancer stem cell behavior and estimation of governing parameters, which determine tumor growth velocity and stem cell density (the project is a part of multi-center collaboration in the NEST framework of European 6-th program).

Consulting of several projects on clinical and biomedical issues.

Work program for 2008

Further implementation of monoclonal antibody PK model to different PD cases including unconjugated antibodies and radioisotope-conjugated antibodies.

Further development of generic model of cancer stem cell, simulation of different stem cell elimination strategies and analysis of biological experiments in which stem cell proliferation and maturation were manipulated.

Publications

Arakelyan L, Vainstain V, and Agur Z. A computer algorithm describing angiogenesis and vessel maturation and its use for studying the effects of anti-angiogenic and anti-maturation therapy on vascular tumor growth, Angiogenesis. 2002; 5(3): pp.203-14.

Vainstein V, Ginosar Y, Shoham M, Yanovsky A, Ranmar D, and Agur Z. 2002. The Complex Effect of Granulocyte Colony-stimulating Factor on Human Granulopoiesis Analyzed by a New Physiologically-based Mathematical Model. J Theor Biol. 2005; 234(3): pp.311-27.

Arakelyan L, Merbl Y, Daugulis P, Ginosar Y, Vainstain V, Kogan Y, Sleitser V, Harpak H and Agur Z. Using multi-scale mathematical modeling in anti-angiogenic therapy, Chap. 7 in "Cancer Modeling and Simulation" Mathematical Biology and Medicine Series, Chapman & Hall/CRC, June 2003; ISBN: 1-58488-361-8.

Vainstein V, Ginosar Y, Shoham M, Ianovski A, Rabinovich A, Kogan Y, Selitser V, and Agur Z. Improving Cancer Therapy by Doxorubicin and Granulocyte Colony-Stimulating Factor: Insights from a Computerized Model of Human Granulopoiesis. MMMP 2007 In press.

Zvia Agur, Moran Elishmereni, Yuri Kogan, Yuri Kheiffetz, Irit Ziv, Meir Shoham, and Vladimir Vainstein. Mathematical modeling as a new approach for improving the efficacy/toxicity profile of drugs: the thrombocytopenia case study In Preclinical Development Handbook, Shayne Gad Ed., John Wiley and Sons, USA. 2008, pp 1229-1266.

Kronik N, Kogan Y, Vainstein V, Agur Z. Improving alloeactive CTL immunotherapy for malignant gliomas using a simulation model of their interactive dynamics. Cancer Immunol Immunother. 2008 Mar;57(3):425-439. Epub 2007 Sep 7.

Abstracts

Vainstein V., Ginosar Y., Shoham M., Ianovski A., Rabinovich A., Kogan Y., Selitser V., Ariad S., Chan S., Agur Z. Clinical validation of a physiologically-based computer model of human granulopoiesis and its use for improving cancer therapy by Doxorubicin and Granulocyte colony-stimulating factor (G-CSF). 48th Annual Meeting of the American Society of Hematology, Orlando, Florida, 9-12 December 2006.

Arakelyan L., Merbl Y., Vainstein V., Agur Z. A new cancer drug regimen based on the interplay between tumor growth and angiogenesis – Predictions of a mathematical model. SIAM Conference on the Life Sciences . Raleigh, North Carolina, 31July – 4 August 2006.

Harpak H, Cohen I, Ginosar Y, Ianovski A, Kogan Y, Shani M, Shoham M, Skomorovski K, Selitser V, Vainstein V & Agur Z. Using In Silico thrombopoiesis tool for identifying mechanisms of drug-induced thrombocytopenia and for defining patients of higher risk, EHO(2003).

Arakelyan L, Vainstain V, and Agur Z. 2002. Optimizing anti-angiogenic therapy using mathematical tools. Proceedings of American Society of Clinical Oncology (ASCO), 21, p. 440a.

Harpak H, Cohen I, Ginosar Y, Ianovski A, Kogan Y, Shani M, Shoham M, Skomorovski K, Selitser V, Vainstein V & Agur Z, Using Virtual thrombopoiesis tool for identifying mechanisms of drug-induced thrombocytopenia and for defining patients of higher risk, Harpak H, Cohen I, Ginosar Y, Ianovski A, Kogan Y, Shani M, Shoham . Hematology Journal. 2003;4(suppl 2):224.